Schering-Plough reaches settlement on Claritin-D 24 hour patent litigation

Schering-Plough Corporation has reached a settlement with Andrx Corporation resolving litigation related to Andrx's generic version of Schering-Plough's Claritin-D 24 Hour Extended Release Tablets. Available as an over-the-counter (OTC) product, Claritin-D 24 Hour Extended Release Tablets is a combination product containing the nonsedating antihistamine loratadine and the decongestant pseudoephedrine. Under terms of the agreement, Schering-Plough has provided a license to a relevant patent pertaining to Claritin-D 24 Hour Extended Release Tablets to Andrx. Financial terms of the settlement were not disclosed.